ZN-c3 free base · Synonyms: Azenosertib | ZN-c3(Compound 16)

ZN-c3 is an orally active, highly potent and selective Wee1 inhibitor.

For research use only. Not for human or veterinary use.

Target Wee1

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

ZN-c3 structure

CAS No.: 2376146-48-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 520.00	BP-02003-250mg	In stock	Get quote
500 mg	USD 850.00	BP-02003-500mg	In stock	Get quote
1 g	USD 1,280.00	BP-02003-1g	In stock	Get quote
5 g	Inquire	BP-02003-5g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

ZN-c3 (Azenosertib) is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer.

Biological activity

In Vitro Azenosertib inhibits proliferations of cancer cells H23 and A427 with IC50s 103 and 75 nM. In Vivo Azenosertib (80 mg/kg; p.o.; 28 days) inhibits tumor growth in A427 xenograft NOD/SCID mice model. Azenosertib (10 mg/kg, p.o.) shows plasma exposure Cmax of 2.1 μM, a half-time T1/2 of 2.3 h, an AUC0-24 h of 9.7 μM·h, and an oralbioavailability of F=142% in beagle dog model.

Identifiers

SMILES: C=CCN1N(C2=CC=C(CC[C@]3(O)CC)C3=N2)C4=NC(NC5=CC=C(N6CCN(CC6)C)C=C5)=NC=C4C1=O
InChIKey: OXTSYWDBUVRXFF-GDLZYMKVSA-N

Specifications

MW (average): 526.6327
Formula: C₂₉H₃₄N₈O₂
CAS No.: 2376146-48-2
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 175 mg/mL

Documents

References

[1]. Meng, Xiangbing et al. “Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. Frontiers in medicine vol. 8 737951. 4 Oct. 2021, doi:10.3389/fmed.2021.737951

[2]. Huang, Peter Q et al. “Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer. Journal of medicinal chemistry vol. 64,17 (2021): 13004-13024. doi:10.1021/acs.jmedchem.1c01121

Same target

Search Wee1

Same research area

Search Cancer